BFRA - Biofrontera anticipates fiscal year sales of Euro30.3M slightly lower from a year ago

Germany based biopharmaceutical company, Biofrontera ([[BFRA]] +0.1%) sees fiscal year 2020 sales of €30.3M - €30.6M, vs. €31.3M, a year ago, attributable to fall in US sales in particular was due to the development of the pandemic crisis situation. However, this was compensated by the positive sales development in Germany.Total sales in Q4 is anticipated at ~€9.6M, down from €12.2M in prior year quarterProduct sales in the US were ~€16.6M, down 29% Y/Y.  Germany product sales amounted to €5.2M up 13% from a year ago. Rest of Europe, generated product sales of ~ €2.1M, down from €2.6M in 2019Effective January 1, 2021, a price increase of ~5% for Ameluz in the US led to stockpiling by some physicians in December 2020, albeit to a lesser extent than in the previous year, which contributed to the strong sales performance in the last quarter of the year.

For further details see:

Biofrontera anticipates fiscal year sales of €30.3M, slightly lower from a year ago